ABSTRACT
Complexes of La(III) with 1-aminocyclopentane-, -hexane, -heptane and -4-ethylcyclohexanecarboxylic acids were obtained. The compounds were characterized by elemental analyses, IR spectroscopy and conductivity measurements. The following general formula was derived: LaL3Cl3 x 5 H2O, where L is the corresponding 1-aminocycloalkanecarboxylic acid. The pharmacological studies showed that all complexes manifested higher cytostatic and cytotoxic effects in comparison with lanthanum chloride. Much higher cytotoxic (anti-P388/D1) and cytostatic (anti-L-1210 and anti-melanoma-B16) activity was found for the lanthanum complex with 1-aminocyclopentanecarboxylic acid.
Subject(s)
Antineoplastic Agents/chemical synthesis , Organometallic Compounds/chemical synthesis , Animals , Antineoplastic Agents/pharmacology , Chemical Phenomena , Chemistry, Physical , Lanthanum/pharmacology , Leukemia L1210/drug therapy , Leukemia P388/drug therapy , Ligands , Melanoma, Experimental/drug therapy , Mice , Organometallic Compounds/pharmacologyABSTRACT
Co(II), Ni(II), Cu(II) and Zn(II) complexes of levamisole (LMS) were prepared and characterized by elemental analyses, IR spectroscopy, 1H and 13C NMR and mass spectrometry. The following general formula was derived: M(LMS)2Cl2, where M = Co, Ni, Cu, Zn. It was established that LMS behaved as a monodentate ligand and the coordination was accomplished through the N-7 atom. The toxicity and the immunomodulating activity of the complexes on mice and rats in comparison with uncomplexed LMS was assayed. The metals in the complexes exerted different changes in the toxicity of LMS. The complex containing Zn(II) was less toxic and manifested higher immunomodulating activity than LMS.
